References
- Wagner BM: To inununostain or not to immunostain, that is the question (editorial). Mod Pathol 6:113, 1993
- Council of the Association of Directors of Anatomic and Surgical Pathology: The incorporation of immunostaining data in anatomic pathology reports (editorial). Mod Pathol 6:238, 1993
- Wilbur DC, Barrows GH: Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis is pure in situ breast carci-noma: An immunohistochemical study. Mod Pathol 6:114, 1993
- Schnitt Si, Silen W, Sadowslcy NL et al: Ductal carcinoma in situ (intraductal carcinoma) of the breast. N Engl J Med 318:898, 1988
- Allred DC, Clark GM, Tandon AK et al: Her-2/neu in node-negative breast cancer: Prognostic significance of overexpres-sion influenced by the presence of in situ carcinoma. J Clin On-col 10:599, 1992
- Gustayson BA, RD Gelber, A Goldhirsch et al: Prognostic im-portance of c-erbB-2 expression of in situ carcinoma. J Clin Oncol 10:1049, 1992
- Poller DN, Snead DRJ, Roberts EC et al: Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and the expression of the c-erbB-2 oncoprotein. Br J Cancer 68:156, 1993
- Bassett P, Wolf C, Chambon P: Expression of the stromelysin 3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues. Breast Cancer Res Treat 245:185, 1993
- Swanson PE: Diagnostic immunohistochemistry. A practical primer for the benighted bureaucrat. Am J Clin Pathol 99:530, 1993